)
Visual
test
Glenmark Pharmaceuticals
Glenmark Pharmaceuticals (GLENMARK) investor relations material
Glenmark Pharmaceuticals Q3 25/26 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 25/26 earnings summary2 Feb, 2026
Executive summary
Consolidated revenue for Q3 FY26 was INR 39,600 million, up 15.1% YoY; nine-month revenue at INR 132,119 million, up 31.3% YoY.
Broad-based growth across India, North America, Europe, and emerging markets, with India and specialty products driving performance.
Innovation-led growth with multiple launches in respiratory, oncology, and dermatology, including new COPD therapies and strong uptake of TEVIMBRA, BRUKINSA, and RYALTRIS.
Unaudited financial results for Q3 and nine months ended 31 December 2025 were approved by the Board on 30 January 2026.
Results include both standalone and consolidated financials, reflecting the performance of the parent and subsidiaries.
Financial highlights
Q3 FY26 consolidated revenue grew 15.1% YoY to INR 39,600 million; nine-month revenue up 31.3% YoY.
EBITDA margin for Q3 FY26 was 22.3%–23%; PAT stood at INR 4,032 million, including an exceptional item of INR 1,843 million due to new labour codes.
Net cash position at INR 1,200 crore as of December 2025; gross debt at INR 600 crore.
R&D expense for the quarter was INR 290 crore, with about 50% related to IGI.
CapEx for the quarter was INR 215 crore; YTD CapEx at INR 715 crore (55% intangible, 45% tangible).
Outlook and guidance
Strong finish to FY26 expected, with continued growth in the U.S. and India, and new respiratory launches anticipated in Q4.
Guidance to maintain EBITDA margin at 23% on a sustainable basis; margin expansion expected from FY28 as innovative assets scale.
Working capital cycle targeted at 115 days by March 2026; currently at 110 days.
CapEx for FY27 expected to be INR 800 crore, focused on plant expansion and in-licensing.
The company continues to monitor the impact of new labour codes and regulatory changes, with provisions recognized for estimated impacts.
Monroe's expected contribution timeline?
What margin uplift from innovative assets by FY28?
US respiratory pipeline beyond Flovent?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- BMY
Growth Portfolio drives double-digit revenue growth as legacy products decline. - DETEC
2025 ended with lower sales and profit, but double-digit growth is forecast for early 2026. - ROCK
2025 revenue up 2.7% ex-Russia; 2026 EBIT margin guided at 13%-14% with high CapEx. - MCFT
Q2 FY2026 sales and margins surged, with guidance raised and a key acquisition announced. - QIGD
Revenue up 2%, net profit down 4%, and cash fell 22% amid higher export costs. - POWERINDIA
Q3 FY26 saw 29.6% revenue growth, 90.3% PAT jump, and a record order backlog. - AURIONPRO
26% revenue growth, strong margins, major wins, and AI-driven expansion mark the period. - XPO
Q4 2025 delivered margin expansion, record LTL service, and flat adjusted EPS year-over-year. - GPRE
Returned to profitability in Q4 2025 with strong margins, tax credits, and debt reduction. - MERUS
Net sales up 52.5% to €54.6m, EBITDA positive, with strong energy storage and power quality orders.
Next Glenmark Pharmaceuticals earnings date
Q4 25/2622 May, 2026
Glenmark Pharmaceuticals
Next Glenmark Pharmaceuticals earnings date
Q4 25/2622 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Glenmark Pharmaceuticals Ltd. is a pharmaceutical company engaged in the research, development, manufacturing, and marketing of generic and specialty medicines. The company operates across multiple therapeutic areas, including dermatology, respiratory, oncology, and cardiovascular diseases. The company is headquartered in Mumbai, India, and its shares are listed on the Bombay Stock Exchange (BSE) and the National Stock Exchange of India (NSE).
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage